AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.
Frequently asked questions
What sector does AmCad BioMed Corporation (4188) operate in?
AmCad BioMed Corporation belongs to the Other sector and operates in the Medical Devices industry.
What is AmCad BioMed Corporation (4188) current stock price?
As of the latest data, AmCad BioMed Corporation stock price is UYU 9.94, with a previous close of UYU 9.95. AmCad BioMed Corporation lost -UYU 0.01 in the last trading session, representing a -0.1% loss.
What is AmCad BioMed Corporation (4188) current market capitalization?
AmCad BioMed Corporation market cap is approximately 629.53 million.
What is AmCad BioMed Corporation (4188) Earnings Per Share (EPS)?
The trailing EPS is -UYU 0.85.
Does AmCad BioMed Corporation (4188) pay dividends?
No. AmCad BioMed Corporation does not pay a dividend.
What is AmCad BioMed Corporation (4188) beta (volatility) score?
AmCad BioMed Corporation has a beta of 0.299, indicating lower volatility than the overall market.
